A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Primary Objective
To evaluate the use of Enfortumab vedotin plus CPI in treatment of advanced bladder cancer
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 17-1410
More information available at ClinicalTrials.gov: NCT03288545
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers